Bioregulator
    Research Only

    Vesugen

    Also known as: Vesugen bioregulator, Lys-Glu-Asp, KED peptide

    Vesugen is a synthetic tripeptide composed of lysine, glutamic acid, and aspartic acid (Lys-Glu-Asp), developed by Professor Vladimir Khavinson as a bioregulator peptide targeting the vascular system. It is designed to support endothelial function and microcirculation by modulating gene expression in vascular endothelial cells. Age-related vascular decline, characterised by endothelial dysfunction, reduced nitric oxide bioavailability, and impaired microcirculation, is a major contributor to cardiovascular disease and organ dysfunction. Vesugen is proposed to interact with DNA in endothelial cells to normalise transcription of genes involved in vascular homeostasis, including those regulating nitric oxide synthesis, angiogenesis, and endothelial integrity.

    View Product

    Research overview

    Vesugen, also known as the KED peptide or Vesugen bioregulator, is a tripeptide bioregulator composed of lysine-glutamic acid-aspartic acid (Lys-Glu-Asp). This research compound belongs to the bioregulator classification and has garnered scientific interest for its proposed interactions with vascular endothelial systems in laboratory studies. Research indicates that Vesugen may penetrate endothelial cell membranes and interact with specific DNA sequences to modulate gene expression related to vascular function in research models. The proposed mechanism involves targeting genes associated with endothelial nitric oxide synthase (eNOS) expression, prostacyclin synthesis, and endothelial cell adhesion molecule regulation. Studies suggest that by potentially restoring youthful gene expression patterns in aging vasculature, this bioregulator may support nitric oxide-dependent vasodilation processes. Primary research effects observed in laboratory studies include support for endothelial function and potential improvements in microcirculation. Research models have demonstrated proposed modulation of nitric oxide synthesis pathways and potential normalisation of vascular gene expression. Additionally, studies indicate that Vesugen may support blood vessel integrity and reduce endothelial inflammation markers in experimental settings. The current evidence base consists primarily of preclinical studies and observational data, with in vitro studies showing effects on endothelial cell gene expression and animal models demonstrating microcirculation improvements. However, researchers should note that no controlled human clinical trials meeting international standards have been published to date, placing the evidence grade at level D. This bioregulator remains an active area of investigation for researchers studying vascular biology and endothelial function mechanisms.

    Mechanism of action

    Vesugen (Lys-Glu-Asp) is theorised to penetrate endothelial cell membranes and interact with specific DNA sequences to modulate gene expression related to vascular function. Proposed targets include genes involved in endothelial nitric oxide synthase (eNOS) expression, prostacyclin synthesis, and endothelial cell adhesion molecule regulation. By potentially restoring youthful gene expression patterns in aging vasculature, Vesugen may support nitric oxide-dependent vasodilation, reduce endothelial inflammation, and improve microcirculatory blood flow.

    Frequently asked questions